|
Synonyms: MEDI3902
Compound class:
Antibody
Comment: Gremubamab (MEDI3902) is a bivalent, bispecific monoclonal antibody [2]. It is under clinical development as a treatment for nosocomial pneumonia caused by Pseudomonas aeruginosa.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| Gremubamab has progressed to Phase 2 clinical evaluation. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02255760 | Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults | Phase 1 Interventional | MedImmune LLC | ||
| NCT02696902 | Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects | Phase 2 Interventional | MedImmune LLC | 1 | |
